2021 News

• 12.07.2021
  IR News

  Santen and Aerie to accelerate global deployment of Rhopressa/Rhokiinsa and Rocklatan/Roclanda Expanding the area of exclusive licensing, including Europe and China

• 11.18.2021
  IR News

  Santen and ActualEyes sign a joint development agreement on Phase II clinical trial (Phase II a / PoC study) for a treatment candidate for Fuchs endothelial corneal dystrophy

• 11.18.2021
  Information

  Santen and Ube Industries receives Complete Response Letter from FDA for STN1011700/DE-117

• 11.12.2021
  IR News

  Santen to Present Latest Data on Omidenepag Isopropyl at AAO 2021

• 11.08.2021
  IR News

  Santen Reports the 2nd Quarter Fiscal 2021 Consolidated Performance

• 10.13.2021
  IR News

  Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution 0.02% Phase 3 Clinical Trial in Japan

• 10.08.2021
  IR News

  Santen to Present Latest Data on STN2000100 (DE-128, MicroShunt) at 39th ESCRS

• 10.01.2021
  IR News

  Notice of Corporate Officer Appointments

• 09.30.2021
  IR News

  Singapore National Eye Centre and Santen Announce a Strategic Partnership to Develop and Deploy Internationally an Innovative Educational Programme for Development of the Eye Care Ecosystem in Asia

• 09.30.2021
  IR News

  Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System

• 09.28.2021
  IR News

  Integrated Report Santen Report 2021 has been published

• 09.03.2021
  IR News

  Santen to Present Latest Data including STN1012700 (DE-127) at APAO 2021

• 09.01.2021
  IR News

  Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System

• 09.01.2021
  IR News

  Notice on the Selection to Apply to New Market Segment 'Prime Market' on the Tokyo Stock Exchange

• 08.31.2021
  IR News

  Santen and Airdoc Partner to Improve Diagnostic Rate of Fundus Ocular Diseases with AI device in China

• 08.30.2021
  IR News

  Santen Files for Manufacturing and Marketing Approval of STN1008903 (diquafosol sodium) - Improved formulation to reduce the frequency of administration to ease patients' burden -

• 08.10.2021
  IR News

  Santen and Sydnexis execute an exclusive licensing agreement for SYD-101, a novel investigational treatment for progressive childhood myopia

• 08.06.2021
  IR News

  Santen Reports the 1st Quarter Fiscal 2021 Consolidated Performance

• 07.29.2021
  IR News

  Santen to Present Latest Data including STN1012700 (DE-127) and STN1007603 (DE-076C) at 33rd APACRS 2021 meeting

• 07.26.2021
  IR News

  Santen and IAPB taking action to implement the first ever UN General Assembly resolution recognizing the link between eye health and sustainable development

• 07.21.2021
  IR News

  Santen to Present Latest Data on STN2000100 at 2021 ASCRS Annual Meeting

• 07.21.2021
  IR News

  Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program

• 07.08.2021
  IR News

  Santen's CO2 emission reduction targets endorsed by the Science Based Targets (SBT) initiative

• 06.28.2021
  IR News

  Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program

• 06.24.2021
  IR News

  Santen Receives U.S. FDA Approval for Verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the Treatment of Vernal Keratoconjunctivitis in Children and Adults

• 06.24.2021
  IR News

  Santen to Present Latest Data on STN2000100 at COS 2021 and 9th WGC

• 06.03.2021
  IR News

  Santen to Present Latest Data on Omidenepag Isopropyl at APGC 2021

• 05.19.2021
  IR News

  Santen Announces Medium-Term Plan "MTP2025"

• 05.19.2021
  IR News

  Santen and Glaukos Enter into a New Collaboration in the Development and Commercialization of STN2000100 (DE-128) in the Americas, Australia, and New Zealand

• 05.18.2021
  IR News

  Santen Establishes "Santen Vision for the Earth 2050" Setting Environmental Targets for 2030, Including CO2 Emissions Reduction Targets

• 05.17.2021
  IR News

  Santen expresses a stance to strengthen its gender diversity. -Joining the "30% Club Japan," taking action to increase gender diversity at board and senior management -Becoming a signatory of the "UN Women's Empowerment Principles" promoting gender equality and women's empowerment in the workplace, marketplace and community

• 05.11.2021
  IR News

  Notice of Board of Director and Corporate Auditor Nominations

• 05.11.2021
  IR News

  Santen Reports Fiscal 2020 Consolidated Performance

• 05.11.2021
  IR News

  Notice of Postponement of Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year

• 04.22.2021
  IR News

  Santen has commenced the construction of the new factory in Suzhou to address expanding product demand in China -Toward reinforcing global production and supply structure-

• 04.09.2021
  IR News

  Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts

• 03.22.2021
  IR News

  Notice of Corporate Officer Appointments

• 03.12.2021
  IR News

  Santen Announces Sponsorship of IBSA Blind Football World Grand Prix for the Second Consecutive Year

• 02.04.2021
  IR News

  (Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year

• 02.04.2021
  IR News

  Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance

• 02.02.2021
  IR News

  Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension

• 02.01.2021
  IR News

  Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea

• 01.08.2021
  IR News

  Santen to Hold a Presentation for the 39th Annual J.P. Morgan Healthcare Conference

• 01.07.2021
  IR News

  Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities

News Archive